Previous

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
Next

Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma